Dr. Pieter Sonneveld on a Prognostic Indicator for Multiple Myeloma

Video
Conference|European Hematology Association Congress

Pieter Sonneveld, MD, PhD, Head of the Department of Hematology, Erasmus University Medical Center, discusses the SKY92 prognostic indicator (MMPROFILER) for multiple myeloma.

Sonneveld and his team collected the DNA of tumors cells of more than 350 newly diagnosed patients with multiple myeloma. They then worked to identify which genes were overactive in the tumor cells of those patients and did a principal component analysis to find out what the most important genes that are relevant for the prognosis of those patients.

Ninety-two genes were identified that represent important pathways in multiple myeloma biology, says Sonneveld. Based on this data, a tool was created that can be used to predict the prognosis of individual myeloma patients or cohorts of patients in large clinical trials.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Related Content
FDA

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024
Article
Paul G. Richardson, MD

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

October 2nd 2023
Podcast
Paul G. Richardson, MD, of Dana-Farber Cancer Institute

Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma

April 18th 2024
Article
Ajay K. Nooka, MD, MPH, FACP

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023
Podcast
Sundar Jagannath, MBBS, of Tisch Cancer Institute, Mount Sinai

Linvoseltamab Elicits Deep Responses in Late-Stage R/R Multiple Myeloma

April 8th 2024
Article
The FDA has approved ciltacabtagene autoleucel (Carvykti; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide (Revlimid).

FDA Approves Cilta-Cel for R/R Multiple Myeloma After at Least One Prior Line of Therapy

April 6th 2024
Article